Affinage

ANXA2

Annexin A2 · UniProt P07355

Length
339 aa
Mass
38.6 kDa
Annotated
2026-06-09
100 papers in source corpus 46 papers cited in narrative 48 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 7/7 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

ANXA2 is a calcium- and phospholipid-binding scaffold protein that integrates membrane biology, tyrosine-kinase signaling, and transcriptional control to drive cell proliferation, migration, invasion, and inflammatory responses (PMID:30081903, PMID:34944416). Its central regulatory event is tyrosine phosphorylation in its N-terminal tail (Tyr23/Tyr24) by Src-family kinases, which is organized by scaffolds and adaptors: RACK1 bridges Src to ANXA2 (PMID:31113450), FOXD1-induced RalA forms a ternary RalA/ANXA2/Src complex that amplifies Tyr23 phosphorylation and ERK1/2 signaling (PMID:36229838), and PFN1 recruits Src to phosphorylate ANXA2 (PMID:39508106); EphA2-activated YES1 phosphorylates Tyr24 (PMID:33941853), and MIEN1 further promotes Tyr23 phosphorylation and cell-surface translocation (PMID:26272794). Phosphorylation drives nuclear translocation, where ANXA2 binds STAT3 to enhance IL-6/EGF-responsive transcription of cyclin D1 and MMP2/9 (PMID:26307676, PMID:28470457, PMID:26253946), and binds and stabilizes MYC to activate HIF1A/VEGF (PMID:30081903); ANXA2 also engages KRAS at the membrane to activate MEK/ERK (PMID:37277019) and promotes Wnt/β-catenin signaling (PMID:38317006). At the cell surface ANXA2 forms the ANXA2/S100A10 (p11) heterotetramer (AIIt), an electrostatically stabilized complex (PMID:11108962) that acts as a plasminogen receptor regulating plasmin generation (PMID:30588744, PMID:34944416). ANXA2 abundance is set by competing post-translational modification: ubiquitination by TRIM65, NEDD4L, and FBXW10 (the latter K63-linked, driving membrane translocation) (PMID:30075204, PMID:35977942, PMID:37277019), opposed by USP4-mediated deubiquitination, acetylation, and the S100A11 stabilizing interaction (PMID:31430050, PMID:40185997); deacetylation by HDAC9 and chaperone binding (HSPA, HSPB1) further tune stability and aggregation (PMID:37690046, PMID:38481805). ANXA2 transcription is itself a regulatory node, repressed by ERG and SRF (PMID:25344575, PMID:35900381) and activated by p-STAT3, MOF/JUN-driven H4K16 acetylation, and XAB2 (PMID:36324154, PMID:38317006, PMID:40069750). Beyond cancer, ANXA2 acts upstream of NF-κB in inflammation and insulin resistance (PMID:30462534, PMID:35900381), serves as a hijacked host factor for assembly/replication of HIV-1, EV71, influenza, and HBV (PMID:19325895, PMID:34196914, PMID:28893180, PMID:34645932), and in neurons is scaffolded by Ahnak into a p11/ANXA2 complex coupled to L-type voltage-gated calcium channels, linking it to calcium signaling and depression-like behavior (PMID:30760886, PMID:37690046).

Mechanistic history

Synthesis pass · year-by-year structured walk · 12 steps
  1. 2000 Medium

    Established the molecular architecture of the ANXA2/p11 heterotetramer, defining how ANXA2 assembles its cell-surface complex.

    Evidence Computational docking validated against cryo-EM projected density maps

    PMID:11108962

    Open questions at the time
    • No mutagenesis confirmation of the electrostatic interface in this work
    • Does not address functional consequences of complex assembly
  2. 2012 Medium

    Linked ANXA2 abundance to a proliferative/invasive program, showing it raises c-myc and cyclin D1 via ERK1/2.

    Evidence Overexpression with pathway readout and xenograft validation in breast cancer cells

    PMID:22452352

    Open questions at the time
    • Mechanism connecting ANXA2 to ERK activation not resolved
    • Direct binding partners not identified
  3. 2015 High

    Identified the ANXA2-STAT3 axis as a direct transcriptional mechanism driving EMT and G1/S progression, moving ANXA2 from membrane protein to nuclear transcriptional co-regulator.

    Evidence Reciprocal Co-IP, siRNA loss-of-function, cell-cycle analysis, and in vivo metastasis models

    PMID:26253946 PMID:26307676

    Open questions at the time
    • Did not establish phosphorylation requirement for STAT3 binding
    • Structural basis of ANXA2-STAT3 interaction unknown
  4. 2014 Medium

    Defined ANXA2 as a transcriptionally repressed target of ERG that maintains epithelial polarity, establishing its cytoskeletal/junctional role and an upstream transcriptional control point.

    Evidence ERG ChIP, promoter binding, immunofluorescence for apical localization and actin, CDC42/RHOA/cofilin analysis

    PMID:25344575

    Open questions at the time
    • Direct ANXA2 effect on Rho GTPases not biochemically dissected
    • Single lab
  5. 2017 High

    Identified Src/YES1-mediated Tyr23/Tyr24 phosphorylation as the switch controlling ANXA2 nuclear translocation and partner engagement, mechanistically connecting kinase input to MYC stabilization and STAT3 sensitization.

    Evidence Phosphomutant constructs, Co-IP, ubiquitination assays, ChIP, reporter assays, xenografts across esophageal and breast cancer

    PMID:28470457 PMID:30081903

    Open questions at the time
    • Tyr23 vs Tyr24 functional distinction not fully separated
    • How phosphorylation alters nuclear import machinery unknown
  6. 2019 High

    Resolved how Src is delivered to ANXA2, identifying RACK1 as the scaffold mediating Src-dependent Tyr23 phosphorylation required for invasion.

    Evidence Reciprocal Co-IP of the RACK1/Src/ANXA2 ternary complex, siRNA, inhibitors, rescue, in vivo metastasis

    PMID:31113450

    Open questions at the time
    • Whether RACK1 acts in all ANXA2-phosphorylating contexts unknown
    • Stoichiometry of the complex not defined
  7. 2019 High

    Established Ahnak as the neuronal scaffold organizing the p11/ANXA2 complex onto the L-type VGCC, linking ANXA2 to calcium currents and depression-like behavior.

    Evidence Co-IP, conditional knockout mice, electrophysiology, behavioral assays

    PMID:30760886

    Open questions at the time
    • Direct contribution of ANXA2 itself (vs p11/Ahnak) to channel regulation not isolated
    • Calcium-binding requirement not tested
  8. 2021 High

    Extended the kinase-input map by showing EphA2-activated YES1 phosphorylates ANXA2 at Tyr24 to drive nuclear localization and invasion, and confirmed AIIt as an oncogene-regulated plasminogen receptor.

    Evidence Phosphomutant (Tyr24F) rescue, knockdown/overexpression, in vivo models; biochemical review of AIIt plasminogen activity

    PMID:33941853 PMID:34944416

    Open questions at the time
    • Crosstalk between Tyr23 and Tyr24 phosphorylation pathways unresolved
    • AIIt review does not add new primary data
  9. 2022 High

    Demonstrated that ANXA2 stability is governed by competing ubiquitination and that ncRNAs and adaptors tune this, with LINC00941 acting as a NEDD4L decoy and RalA amplifying Src phosphorylation.

    Evidence RNA pulldown/MS, domain-mapped Co-IP, GST-pulldown, ChIP-seq, in vivo CTC models

    PMID:35977942 PMID:36229838

    Open questions at the time
    • Hierarchy among competing E3 ligases unknown
    • Ubiquitination site mapping incomplete in some cases
  10. 2022 Medium

    Positioned ANXA2 transcription as a tunable node, repressed by SRF and activated by p-STAT3, coupling it to NF-κB-driven inflammation, pyroptosis, and fibrosis.

    Evidence ChIP/ChIP-seq, reporter assays, Co-IP, knockdown, disease mouse models (pancreatitis, NASH)

    PMID:30462534 PMID:35900381 PMID:36324154

    Open questions at the time
    • Direct biochemical link between ANXA2 and p50 nuclear translocation not defined
    • Tissue specificity of regulation unclear
  11. 2024 High

    Defined an additional ubiquitin/acetylation/chaperone layer—USP4, HDAC9, HSPB1, HSPA, MOF/USP10—that controls ANXA2 stability, aggregation, and downstream STAT3/BMX, autophagy, and redox outputs.

    Evidence Linkage-specific ubiquitination assays, IP-MS, acetylation/phospho mutants, multiple KO mouse models, ChIP-seq

    PMID:37690046 PMID:38290972 PMID:38317006 PMID:38481805 PMID:40185997

    Open questions at the time
    • Integration of multiple PTMs into a unified regulatory logic not established
    • Many axes characterized in single labs/single disease contexts
  12. 2024 Medium

    Broadened ANXA2's functional reach to receptor-coupled signaling (TIM-4/PI3K-AKT, NINJ1/TLR4, exosomal ANXA2/TLR2) and host-pathogen biology across multiple viruses.

    Evidence Co-IP/MS, competitive binding, conditional KO mice, inhibitor co-culture, viral titer and replication assays

    PMID:19325895 PMID:28893180 PMID:34196914 PMID:34645932 PMID:36806050 PMID:38922800 PMID:39709496

    Open questions at the time
    • Whether membrane vs nuclear vs surface ANXA2 pools mediate these distinct functions not delineated
    • Several interactions rest on single-lab Co-IP

Open questions

Synthesis pass · forward-looking unresolved questions
  • How the calcium/phospholipid-binding biochemistry of ANXA2 is mechanistically coupled to its phosphorylation-dependent nuclear and surface functions, and how competing PTMs are prioritized in a given cell, remains unresolved.
  • No unifying structural model linking membrane binding to nuclear translocation
  • No reconstitution of the full PTM-stability network
  • Relative contributions of monomeric ANXA2 vs AIIt heterotetramer in each phenotype undefined

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0060090 molecular adaptor activity 5 GO:0001618 virus receptor activity 3 GO:0003723 RNA binding 3 GO:0008289 lipid binding 3 GO:0098772 molecular function regulator activity 2
Localization
GO:0005886 plasma membrane 4 GO:0005634 nucleus 3 GO:0005829 cytosol 2 GO:0005856 cytoskeleton 2
Pathway
R-HSA-162582 Signal Transduction 4 R-HSA-1643685 Disease 4 R-HSA-392499 Metabolism of proteins 4 R-HSA-74160 Gene expression (Transcription) 4 R-HSA-168256 Immune System 3 R-HSA-9612973 Autophagy 2
Partners
AHNAKKRASMYCRACK1RALAS100A10SRCSTAT3
Complex memberships
ANXA2/S100A10 (p11) heterotetramer (AIIt)Ahnak/p11/ANXA2 neuronal complexRACK1/Src/ANXA2 complexRalA/ANXA2/Src complex

Evidence

Reading pass · 48 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2015 ANXA2 directly binds STAT3 and enhances its transcriptional activity, promoting EGF-induced epithelial-mesenchymal transition in breast cancer cells in a STAT3-dependent manner. Co-immunoprecipitation, knockdown (siRNA), in vitro migration/invasion assays, in vivo metastasis model Oncotarget High 26307676
2017 Phosphorylation of ANXA2 at Tyr23 by SRC kinase drives its nuclear translocation; nuclear phospho-ANXA2(Tyr23) interacts with MYC, inhibiting MYC's ubiquitin-dependent proteasomal degradation, thereby stabilizing MYC which then activates HIF1A transcription and downstream VEGF expression to promote esophageal cancer metastasis. Co-immunoprecipitation, ubiquitination assay, ChIP, reporter assay, confocal immunofluorescence, siRNA knockdown, in vivo xenograft Journal of experimental & clinical cancer research High 30081903
2017 Tyr23 phosphorylation of ANXA2 is required for its interaction with STAT3 and for enhancing STAT3 sensitivity to IL-6 activation, leading to increased cyclin D1 and MMP2/9 expression and promoting breast cancer cell proliferation and invasion. Co-immunoprecipitation, phosphomutant constructs (Tyr23), Western blot, in vitro and in vivo functional assays Breast cancer research and treatment High 28470457
2019 RACK1 acts as a scaffold protein that mediates the interaction between SRC kinase and ANXA2, facilitating Src-dependent phosphorylation of ANXA2 at Tyr23, which is required for invasion and metastasis in multidrug-resistant breast cancer cells. Co-immunoprecipitation, siRNA knockdown, small molecule inhibitors, rescue experiments, in vivo metastasis model Breast cancer research High 31113450
2021 EphA2 activates YES1 kinase, which phosphorylates ANXA2 at Tyr24, leading to ANXA2 activation and increased nuclear localization; reexpression of wild-type but not Tyr24F mutant ANXA2 in ANXA2-KD cells restores YES1-induced invasion and migration in gastric cancer. Knockdown, overexpression, phosphomutant rescue (Tyr24F), in vitro invasion/migration assays, in vivo tumor growth models Oncogene High 33941853
2016 P-glycoprotein (P-gp) interacts with ANXA2 and promotes invasion of multidrug-resistant breast cancer cells by modulating Src-dependent tyrosine phosphorylation of ANXA2; P-gp also interacts with Src kinase upstream of ANXA2. Co-immunoprecipitation, co-localization, P-gp inhibitors and MDR1 knockdown, Western blot International journal of molecular sciences Medium 24239898 27754360
2000 The ANXA2/S100A10 (p11) heterotetramer complex structure was modeled by docking algorithms against cryo-electron microscopy projected density maps, revealing that the interaction between the ANXA2 core and p11 is primarily electrostatic in character, stabilized through charged residues. Computational docking with validation against cryo-EM projected density maps Biochimica et biophysica acta Medium 11108962
2018 TRIM65 E3 ubiquitin ligase ubiquitinates ANXA2, promoting its degradation and thereby modulating cytoskeleton rearrangement and EMT in bladder cancer cells. Ubiquitination assay, Co-IP, siRNA knockdown, in vitro and in vivo functional assays Cancer letters Medium 30075204
2022 LINC00941 (lncRNA) directly binds the Annexin 1 domain of ANXA2 and acts as a decoy to prevent NEDD4L (E3 ligase) from binding the same domain, thereby suppressing NEDD4L-mediated ubiquitin-proteasomal degradation of ANXA2, leading to ANXA2 stabilization and FAK/AKT signaling activation in pancreatic cancer. RNA pulldown, mass spectrometry, RIP, Co-IP/MS, knockdown and rescue experiments Cell death & disease High 35977942
2019 Ahnak scaffolds a trimeric complex of Ahnak/p11(S100A10)/ANXA2 in hippocampal neurons; through its N-terminal region Ahnak binds the L-type VGCC pore-forming α1 subunit, and through its C-terminal region it bridges the β subunit and the p11/ANXA2 complex. Ahnak knockout reduces L-type calcium current and channel surface expression, and phenocopies p11 knockout depression-like behavior. Co-IP, knockout mouse models (constitutive and cell-type-specific), electrophysiology, behavioral assays, fractionation Molecular psychiatry High 30760886
2009 ANXA2 interacts with HIV-1 Gag at phosphatidylinositol (4,5) bisphosphate-containing lipid raft membrane domains where Gag mediates viral assembly; ANXA2 expression in 293T cells increases Gag processing and HIV-1 production. Bimolecular fluorescence complementation, overexpression, HIV-1 titer measurement PloS one Medium 19325895
2015 MIEN1 physically interacts with ANXA2 (confirmed by FRET); ITAM-phosphorylated MIEN1 enhances Tyr23 phosphorylation of ANXA2 and stimulates ANXA2 cell-surface translocation, increasing ANXA2 proteolytic activity and tumor cell motility. FRET, Co-immunoprecipitation, Western blot, wound healing assay, phosphomutant constructs Molecular cancer Medium 26272794
2021 ANXA2 interacts with EV71 3D polymerase (RNA-dependent RNA polymerase) via its annexin domain, localizes to viral replication organelles (ROs), and interacts with PI4KB; ANXA2 overexpression stimulates PI4P formation and promotes the PI4KB-3D interaction, facilitating EV71 RNA replication complex assembly and viral replication. Co-immunoprecipitation, knockout cell lines, confocal localization, PI4P quantification, overexpression Virologica Sinica Medium 34196914
2017 ANXA2 interacts with influenza NS1 protein in the cell cytoplasm; ANXA2 overexpression significantly increases H5N1 HPAIV titer while siRNA-mediated knockdown inhibits viral protein expression and reduces progeny virus titer. Co-immunoprecipitation, confocal co-localization, siRNA knockdown, overexpression, viral titer assay BMC microbiology Medium 28893180
2015 ANXA2 depletion inhibits EGF-induced STAT3 phosphorylation and downstream cyclin D1 expression, decelerating G1-to-S phase transition and reducing breast cancer cell proliferation; the effect is mediated through STAT3 as a key transcriptional regulator of cyclin D1. siRNA knockdown, cell cycle analysis (flow cytometry), Western blot, qRT-PCR Breast cancer research and treatment Medium 26253946
2012 ANXA2 upregulation promotes breast cancer cell proliferation, migration, and invasion by increasing c-myc and cyclin D1 expression via activation of Erk1/2 signaling pathways. Overexpression, Western blot, in vitro migration/invasion assays, in vivo xenograft Cell proliferation Medium 22452352
2023 FBXW10 promotes K63-linked polyubiquitination of ANXA2 in a process requiring S6K1-mediated phosphorylation; K63-ubiquitinated ANXA2 translocates from cytoplasm to cell membrane, binds KRAS, and activates the MEK/ERK pathway to drive hepatocellular carcinoma proliferation and metastasis. Ubiquitination assays (K63-linkage specific), Co-IP, subcellular fractionation, knockdown, in vitro and in vivo functional assays Cancer letters Medium 37277019
2014 ERG oncoprotein directly binds the ANXA2 promoter and transcriptionally represses ANXA2 expression; ERG-mediated ANXA2 repression disrupts apical ANXA2 localization, actin bundling at cell-cell junctions, and epithelial cell polarity, promoting EMT through inhibition of CDC42/RHOA and cofilin activation. ERG siRNA, ChIP defining promoter binding, immunofluorescence for apical ANXA2 localization, gain- and loss-of-function, immunohistochemistry Molecular cancer research Medium 25344575
2018 ANXA2 knockdown in obesity-induced insulin-resistant cells inhibits NF-κB p50 nuclear translocation, reduces pro-inflammatory cytokines (IL-6, IL-1β, TNF-α) and SOCS3, and restores insulin signaling (IRS1 phosphorylation, glucose uptake), placing ANXA2 upstream of NF-κB in obesity-induced insulin resistance. siRNA knockdown in palmitic acid-induced IR cell model, high-fat diet mouse model, glucose tolerance test, Western blot, flow cytometry American journal of physiology. Cell physiology Medium 30462534
2019 S100A11 interacts with ANXA2 and decreases ubiquitination and proteasomal degradation of ANXA2; this stabilizes ANXA2 which activates NF-κB signaling; NF-κB in turn transcriptionally activates S100A11, forming a positive feedback loop that promotes GBM progression. Co-immunoprecipitation, ubiquitination assay, knockdown/overexpression, in vivo orthotopic xenograft Journal of cellular and molecular medicine Medium 31430050
2022 p-STAT3 (phospho-STAT3) binds to the Anxa2 promoter and drives its transcription; elevated ANXA2 then promotes caspase-1-mediated hepatocyte pyroptosis and fibrosis in non-alcoholic steatohepatitis; inhibition of p-STAT3 suppresses pyroptosis which is rescued by ANXA2 overexpression. ChIP-seq, ChIP-qPCR, promoter reporter assay, siRNA knockdown, overexpression, NASH mouse model, in vitro NASH model Journal of translational medicine Medium 36324154
2024 DBT (dihydrolipoamide branched chain transacylase E2) interacts with ANXA2 via its lipoyl-binding domain; the DBT-ANXA2 interaction activates Hippo signaling, decreasing nuclear YAP localization and repressing transcription of lipogenic genes in clear cell renal cell carcinoma. Co-immunoprecipitation, mass spectrometry, mutational studies, luciferase reporter assay, subcellular fractionation, in vitro and in vivo functional assays Cancer communications Medium 36860124
2022 USP4 deubiquitinase interacts with ANXA2, cleaving Lys48- and Lys63-linked polyubiquitin chains; Lys63-linked ubiquitination of ANXA2 at K28 specifically mediates Y24 phosphorylation; K10 acetylation of ANXA2 enhances its interaction with USP4. USP4-stabilized ANXA2 promotes GSC maintenance and radioresistance through BMX-mediated STAT3 activation. Co-IP, ubiquitination assays (linkage-specific), acetylation mutant constructs, phosphomutant (Y24), knockdown, in vivo models Cell death and differentiation Medium 40185997
2024 HDAC9 interacts with ANXA2 (identified by IP-MS) and deacetylates it; this interaction inhibits ubiquitinated ANXA2 degradation, stabilizing ANXA2 and mediating depression-like behavior; HDAC9 knockdown/knockout in hippocampal neurons alleviates depression phenotypes. Immunoprecipitation-mass spectrometry, Co-IP, HDAC9 knockdown/knockout mouse model, behavioral assays Cellular and molecular life sciences Medium 37690046
2018 LUCAT1 lncRNA inhibits phosphorylation of ANXA2, which reduces degradation of the ANXA2-S100A10 heterotetramer (AIIt), resulting in accelerated conversion of plasminogen to plasmin and activation of metalloprotease proteins in hepatocellular carcinoma. RNA pulldown, Western blot, loss/gain-of-function experiments Journal of cellular and molecular medicine Medium 30588744
2024 ANXA2 upregulates phosphorylation of HSF1, leading to transcriptional activation of ATG7; MTORC2 is required for ANXA2-mediated ATG7 transcription by HSF1 and contributes to ANXA2 protein stability; HSPA (Hsp70) interacts with ANXA2 and may protect it from lysosomal proteolysis. ANXA2-driven autophagy contributes to TNBC tumor aggressiveness. Bafilomycin A1 autophagic flux assay, ChIP, Western blot, Co-IP for ANXA2-HSPA interaction, siRNA knockdown, in vivo xenograft Autophagy Medium 38290972
2024 Hspb1 directly interacts with Anxa2, decreasing Anxa2 aggregation and phosphorylation; Hspb1 also uses Anxa2 as an intermediary to interact with and maintain the antioxidative activity of Prdx1 by reducing Thr-90 phosphorylation of Prdx1; Hspb1 overexpression did not protect acinar-specific Prdx1-KO mice, establishing the Hspb1/Anxa2/Prdx1 axis for ROS control in acute pancreatitis. Co-IP, Hspb1 KO and Anxa2 KO mice, AAV8-Hspb1 overexpression, acinar-specific Prdx1 KO mice, ROS measurements, phosphorylation analysis International journal of biological sciences High 38481805
2017 SMN depletion reduces axonal transport of ANXA2 mRNA in motor neuron-like cells; a G-rich motif near the 3'UTR of Anxa2 mRNA is required for its axonal localization; mutations in this motif abolish targeting of Anxa2 reporter mRNAs to axon-like structures in SMN-sufficient cells, and localization is restricted to cell body in SMN-depleted cells. SMN depletion, reporter mRNA localization assays, site-directed mutagenesis of 3'UTR G-rich motif, fluorescence imaging in differentiated NSC-34 cells RNA Medium 28258160
2022 ANXA2 knockdown in renal tubular epithelial cells globally alters transcription and alternative splicing of inflammatory response genes, including chemokine CCL5, interferon-regulating genes (ISG15, IFI6, IFI44, IFITM1, IRF7), and alternative splicing of UBA52, RBCK1, and LITAF, indicating ANXA2 regulates inflammatory signaling at the level of gene expression and RNA processing. RNA-sequencing of ANXA2-knockdown HK2 cells, qRT-PCR validation, bioinformatics pathway analysis BMC genomics Medium 35906541
2021 The ANXA2/S100A10 heterotetramer (AIIt) functions as a cell surface plasminogen receptor that both promotes plasmin formation at the cell surface and regulates plasmin destruction; AIIt is activated by oncogenes including SRC, RAS, HIF1α, and PML-RAR and is epigenetically regulated by DNA methylation. Review synthesizing biochemical reconstitution, Co-IP, and genetic studies from multiple labs (cited primary literature) Biomolecules Medium 34944416
2022 FOXD1 transcriptionally induces RalA expression; RalA forms a complex with ANXA2 and Src, enhancing the ANXA2-Src interaction and increasing Tyr23 phosphorylation of ANXA2, which activates ERK1/2 signaling to promote circulating tumor cell formation and breast cancer metastasis; inhibiting RalA-GTP form attenuates ANXA2-Src interaction. GST-pulldown, Co-IP, ChIP-seq, CUT&Tag-seq, in vivo CTC models, ERK1/2 inhibitor treatment Journal of experimental & clinical cancer research Medium 36229838
2024 PFN1 (profilin-1) interacts with phospho-ANXA2 by recruiting Src kinase to phosphorylate ANXA2, which promotes STAT3 phosphorylation and transcriptional activity, driving VSMC phenotype switching and neointimal hyperplasia. Co-IP, single-cell RNA sequencing, SMC-specific PFN1 knockout mice, Western blot, wire-injury neointimal hyperplasia model Arteriosclerosis, thrombosis, and vascular biology Medium 39508106
2024 ADAM8 metalloproteinase binds ANXA2 and promotes phosphorylation of ANXA2 at Ser26; ADAM8 knockout impedes ANXA2 Ser26 phosphorylation, which in turn inhibits mTOR Ser2448 phosphorylation and activates autophagy in macrophages, promoting cardiac repair after myocardial infarction. COIP/mass spectrometry, macrophage-specific ADAM8 KO mice, AAV6-overexpression, phosphorylation analysis, autophagy markers Journal of advanced research Medium 39097092
2021 The S100A10/ANXA2 complex facilitates exocytosis of HBV virions across trophoblast cells; HBV virions co-localize with S100A10/ANXA2 and the autophagosome marker LC3; knockdown of either AnxA2 or S100A10 reduces the amount of exo-virus in Transwell assays. Co-localization (confocal), knockdown, Transwell exocytosis assay, immunohistochemistry of placental tissues Laboratory investigation Medium 34645932
2024 ANXA2 mediates endocytosis of microplastics into breast cancer cells; once internalized, MPs bound to ANXA2 regulate mitophagy by inhibiting IL-17 exocytosis, causing mitochondrial damage. MPs pulldown experiments, mass spectrometry, endocytosis/mitophagy assays, Western blot Environmental pollution Low 39557355
2017 ANXA2 promotes LDL receptor availability and thereby regulates LDL-C levels by serving as an endogenous inhibitor of PCSK9; the ANXA2 repeat-1 (R1) domain binds PCSK9 and blocks its ability to promote LDL-R degradation; the coding SNP V98L in ANXA2-R1 is associated with higher LDL-C and CHD risk. SNP genotype-phenotype association, allele-specific protein binding assay, reporter gene assay, eQTL analysis in human cohorts Atherosclerosis Medium 28456096
2019 HE4 interacts with ANXA2 and MMP2 to form a trimeric HE4-ANXA2-MMP2 protein complex; ANXA2 acts as a bridge mediating HE4 regulation of MMP2 expression and promoting cancer cell migration. Co-immunoprecipitation, double-labeling immunofluorescence, siRNA knockdown, migration/invasion assays Cancer cell international Low 31210752
2021 FLNA (filamin A) interacts with ANXA2 (confirmed by Co-IP) and together they activate the Wnt/β-catenin pathway, contributing to gefitinib resistance in NSCLC; SP1 transcriptionally activates FLNA to regulate this resistance pathway. Co-immunoprecipitation, ChIP for SP1-FLNA promoter binding, siRNA knockdown, overexpression, in vivo mouse models Molecular and cellular biochemistry Medium 34018148
2022 SRF (serum response factor) transcription factor binds the ANXA2 promoter and represses its expression; ANXA2 activates NF-κB signaling by inducing nuclear translocation of p50; thus SRF-mediated repression of ANXA2 protects against pancreatitis-associated NF-κB activation. Dual luciferase reporter assay, ChIP, Co-IP, siRNA knockdown, in vivo AP mouse model Inflammation research Medium 35900381
2024 MOF histone acetyltransferase (KAT8), stabilized by USP10 deubiquitination at K410, promotes H4K16 acetylation at the ANXA2 promoter in a JUN-dependent manner to transcriptionally activate ANXA2, which subsequently activates Wnt/β-catenin signaling to drive ESCC progression; catalytically inactive MOF fails to promote ANXA2 transcription. ChIP-seq, Co-IP, siRNA/overexpression with catalytic mutant (MOF-E350Q), in vitro and in vivo functional assays Oncogene Medium 38317006
2025 USP10 nuclear expression increases upon oxaliplatin treatment, binds XAB2, and deubiquitinates K48-linked polyubiquitination at K593 of XAB2 to stabilize it; XAB2 then binds the ANXA2 promoter (by ChIP) to transcriptionally upregulate ANXA2, promoting DNA damage repair and oxaliplatin resistance in CRC. Co-IP, mass spectrometry for ubiquitination sites, ChIP-seq, ChIP-qPCR, dual-luciferase reporter, ubiquitin assay, functional assays Journal of experimental & clinical cancer research Medium 40069750
2024 m7G-modified tsRNA (mtiRL), catalyzed by METTL1, specifically binds ANXA2 and promotes its Tyr24 phosphorylation by enhancing the interaction between ANXA2 and YES1 kinase, leading to increased nuclear localization of p-ANXA2-Y24 and bladder cancer malignancy. RNA-protein binding assays, small RNA sequencing, m7G modification chip, Co-IP for ANXA2-YES1 interaction, knockdown/overexpression, in vitro and in vivo models Advanced science Medium 38894581
2023 NINJ1 competitively binds ANXA2, an inhibitory interacting protein of TLR4, thereby blocking the ANXA2-TLR4 interaction and activating TLR4 signaling; macrophage-specific NINJ1 deficiency inhibits AAA formation and reduces macrophage infiltration via the TLR4/NF-κB/CCR2 pathway. Protein-protein interaction analysis, Co-IP, macrophage-specific KO mice (Ninj1flox/flox Lyz2-Cre), RNA-sequencing, in vitro and in vivo functional assays Advanced science Medium 38922800
2024 ANXA2 promotes TIM-4-induced mitochondrial fusion by interacting with TIM-4 to promote PI3K/AKT pathway activation, which increases L-OPA1 protein expression and oxidative phosphorylation in lung cancer cells. Co-IP, siRNA knockdown, PI3K inhibitor treatment, Western blot for OPA1/mitochondrial fusion markers, proliferation assays Cell death & disease Medium 36806050
2024 ANXA2 promotes GBM progression by activating BMX-mediated STAT3 activation; USP4-mediated stabilization of ANXA2 (through deubiquitination) and its K10 acetylation enhance this pathway to support GSC maintenance and radioresistance. Co-IP, knockdown, overexpression, GSC functional assays, in vivo models (cited in same paper as USP4 findings) Cell death and differentiation Medium 40185997
2015 ANXA2 knockdown in prostate epithelial cells (via ERG siRNA) enhances apical ANXA2 localization, promotes bundling of actin filaments at cell-cell junctions, and maintains epithelial polarity; conversely, ERG-driven transcriptional repression of ANXA2 disrupts ANXA2-mediated polarity by inhibiting CDC42 and RHOA and activating cofilin, promoting EMT. ERG siRNA, immunofluorescence for apical ANXA2 localization and actin, Western blot for CDC42/RHOA/cofilin, ChIP for ERG promoter binding Molecular cancer research Medium 25344575
2024 Exosomal ANXA2 secreted by ovarian cancer cells binds TLR2 on human peritoneal mesothelial cells (HPMCs), activating HPMCs and shifting their phenotype toward mesenchymal cells, increasing LCN2 expression, which in turn promotes ovarian cancer cell adhesion, proliferation, motility, and lipid metabolism reprogramming. ANXA2 inhibitor (LCKLSL) and TLR2 inhibitor (C29) co-culture experiments, RNA-seq of HPMCs, Co-IP, in vivo OvCa xenograft models Cell communication and signaling Medium 39709496
2021 ANXA2 knockdown in acute pancreatitis model cells reduces NF-κB activation (p50 nuclear translocation), inflammation, and apoptosis; the ANXA2 promoter is bound and repressed by SRF, and ANXA2 directly interacts with the NF-κB pathway. siRNA knockdown, AP model (cerulein/LPS), dual luciferase reporter, ChIP, Co-IP, flow cytometry Inflammation research Medium 35900381

Source papers

Stage 0 corpus · 100 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2017 Mesenchymal Stem Cells Promote Hepatocarcinogenesis via lncRNA-MUF Interaction with ANXA2 and miR-34a. Cancer research 208 28947421
2017 Cancer-associated fibroblasts promote epithelial-mesenchymal transition and EGFR-TKI resistance of non-small cell lung cancers via HGF/IGF-1/ANXA2 signaling. Biochimica et biophysica acta. Molecular basis of disease 123 29253515
2014 MicroRNA-206 functions as a pleiotropic modulator of cell proliferation, invasion and lymphangiogenesis in pancreatic adenocarcinoma by targeting ANXA2 and KRAS genes. Oncogene 109 25500542
2018 ANXA2 promotes esophageal cancer progression by activating MYC-HIF1A-VEGF axis. Journal of experimental & clinical cancer research : CR 108 30081903
2019 The miR155HG/miR-185/ANXA2 loop contributes to glioblastoma growth and progression. Journal of experimental & clinical cancer research : CR 107 30898167
2021 Exosomal LncRNA LINC00659 transferred from cancer-associated fibroblasts promotes colorectal cancer cell progression via miR-342-3p/ANXA2 axis. Journal of translational medicine 102 33407563
2017 Circular RNA profiling reveals that circular RNAs from ANXA2 can be used as new biomarkers for multiple sclerosis. Human molecular genetics 101 28651352
2015 Anxa2 binds to STAT3 and promotes epithelial to mesenchymal transition in breast cancer cells. Oncotarget 84 26307676
2020 S100A11/ANXA2 belongs to a tumour suppressor/oncogene network deregulated early with steatosis and involved in inflammation and hepatocellular carcinoma development. Gut 77 31919231
2009 Anxa2 plays a critical role in enhanced invasiveness of the multidrug resistant human breast cancer cells. Journal of proteome research 72 19764771
2021 EphA2-YES1-ANXA2 pathway promotes gastric cancer progression and metastasis. Oncogene 69 33941853
2018 TRIM65 supports bladder urothelial carcinoma cell aggressiveness by promoting ANXA2 ubiquitination and degradation. Cancer letters 67 30075204
2021 LncRNA MIR155HG induces M2 macrophage polarization and drug resistance of colorectal cancer cells by regulating ANXA2. Cancer immunology, immunotherapy : CII 66 34562123
2011 Peripheral blood monocyte-expressed ANXA2 gene is involved in pathogenesis of osteoporosis in humans. Molecular & cellular proteomics : MCP 60 21817168
2015 MIEN1, a novel interactor of Annexin A2, promotes tumor cell migration by enhancing AnxA2 cell surface expression. Molecular cancer 59 26272794
2019 Crucial role of Anxa2 in cancer progression: highlights on its novel regulatory mechanism. Cancer biology & medicine 58 31908887
2018 Long non-coding RNA LUCAT1 promotes tumourigenesis by inhibiting ANXA2 phosphorylation in hepatocellular carcinoma. Journal of cellular and molecular medicine 57 30588744
2022 LINC00941 promotes pancreatic cancer malignancy by interacting with ANXA2 and suppressing NEDD4L-mediated degradation of ANXA2. Cell death & disease 55 35977942
2013 P-glycoprotein associates with Anxa2 and promotes invasion in multidrug resistant breast cancer cells. Biochemical pharmacology 55 24239898
2019 NUDT21 inhibits bladder cancer progression through ANXA2 and LIMK2 by alternative polyadenylation. Theranostics 54 31695759
2019 Ahnak scaffolds p11/Anxa2 complex and L-type voltage-gated calcium channel and modulates depressive behavior. Molecular psychiatry 53 30760886
2012 Up-regulation of Anxa2 gene promotes proliferation and invasion of breast cancer MCF-7 cells. Cell proliferation 53 22452352
2019 lncRNA LINC00460 Silencing Represses EMT in Colon Cancer through Downregulation of ANXA2 via Upregulating miR-433-3p. Molecular therapy. Nucleic acids 51 32069703
2023 N6-methyladenosine-modified DBT alleviates lipid accumulation and inhibits tumor progression in clear cell renal cell carcinoma through the ANXA2/YAP axis-regulated Hippo pathway. Cancer communications (London, England) 49 36860124
2019 S100A11 functions as novel oncogene in glioblastoma via S100A11/ANXA2/NF-κB positive feedback loop. Journal of cellular and molecular medicine 49 31430050
2017 miR-101 alleviates chemoresistance of gastric cancer cells by targeting ANXA2. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 46 28609840
2017 Tyr23 phosphorylation of Anxa2 enhances STAT3 activation and promotes proliferation and invasion of breast cancer cells. Breast cancer research and treatment 45 28470457
2020 Interference of Hsa_circ_0003928 Alleviates High Glucose-Induced Cell Apoptosis and Inflammation in HK-2 Cells via miR-151-3p/Anxa2. Diabetes, metabolic syndrome and obesity : targets and therapy 42 32982348
2014 Overexpression of ANXA2 predicts adverse outcomes of patients with malignant tumors: a systematic review and meta-analysis. Medical oncology (Northwood, London, England) 41 25476478
2023 TIM-4 orchestrates mitochondrial homeostasis to promote lung cancer progression via ANXA2/PI3K/AKT/OPA1 axis. Cell death & disease 40 36806050
2022 The p-STAT3/ANXA2 axis promotes caspase-1-mediated hepatocyte pyroptosis in non-alcoholic steatohepatitis. Journal of translational medicine 40 36324154
2019 Rack1 mediates tyrosine phosphorylation of Anxa2 by Src and promotes invasion and metastasis in drug-resistant breast cancer cells. Breast cancer research : BCR 38 31113450
2024 ANXA2 (annexin A2) is crucial to ATG7-mediated autophagy, leading to tumor aggressiveness in triple-negative breast cancer cells. Autophagy 37 38290972
2024 Hspb1 protects against severe acute pancreatitis by attenuating apoptosis and ferroptosis via interacting with Anxa2 to restore the antioxidative activity of Prdx1. International journal of biological sciences 35 38481805
2021 Exosomal ANXA2 derived from ovarian cancer cells regulates epithelial-mesenchymal plasticity of human peritoneal mesothelial cells. Journal of cellular and molecular medicine 35 34725902
2024 Proteomic analysis identifies HSP90AA1, PTK2B, and ANXA2 in the human entorhinal cortex in Alzheimer's disease: Potential role in synaptic homeostasis and Aβ pathology through microglial and astroglial cells. Brain pathology (Zurich, Switzerland) 34 38247340
2022 Hypoxia-induced circADAMTS6 in a TDP43-dependent manner accelerates glioblastoma progression via ANXA2/ NF-κB pathway. Oncogene 34 36396726
2009 Anx2 interacts with HIV-1 Gag at phosphatidylinositol (4,5) bisphosphate-containing lipid rafts and increases viral production in 293T cells. PloS one 34 19325895
2019 High Expression of ANXA2 Pseudogene ANXA2P2 Promotes an Aggressive Phenotype in Hepatocellular Carcinoma. Disease markers 31 30881525
2018 Effects of MicroRNA-206 on Osteosarcoma Cell Proliferation, Apoptosis, Migration and Invasion by Targeting ANXA2 Through the AKT Signaling Pathway. Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology 31 29462818
2024 A Novel tsRNA, m7G-3' tiRNA LysTTT, Promotes Bladder Cancer Malignancy Via Regulating ANXA2 Phosphorylation. Advanced science (Weinheim, Baden-Wurttemberg, Germany) 30 38894581
2023 Isoliquiritigenin alleviates the development of alcoholic liver fibrosis by inhibiting ANXA2. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 29 36680814
2025 USP10/XAB2/ANXA2 axis promotes DNA damage repair to enhance chemoresistance to oxaliplatin in colorectal cancer. Journal of experimental & clinical cancer research : CR 28 40069750
2021 A novel regulatory loop miR-101/ANXA2/EGR1 mediates malignant characteristics of liver cancer stem cells. Carcinogenesis 26 32531042
2019 Long noncoding RNA cytoskeleton regulator RNA promotes cell invasion and metastasis by titrating miR-613 to regulate ANXA2 in nasopharyngeal carcinoma. Cancer medicine 26 31859457
2018 Anxa2 gene silencing attenuates obesity-induced insulin resistance by suppressing the NF-κB signaling pathway. American journal of physiology. Cell physiology 26 30462534
2018 The interaction between ANXA2 and lncRNA Fendrr promotes cell apoptosis in caerulein-induced acute pancreatitis. Journal of cellular biochemistry 26 30474876
2017 Annexin A2 (ANXA2) interacts with nonstructural protein 1 and promotes the replication of highly pathogenic H5N1 avian influenza virus. BMC microbiology 26 28893180
2016 Rack1 Mediates the Interaction of P-Glycoprotein with Anxa2 and Regulates Migration and Invasion of Multidrug-Resistant Breast Cancer Cells. International journal of molecular sciences 26 27754360
2022 FOXD1-dependent RalA-ANXA2-Src complex promotes CTC formation in breast cancer. Journal of experimental & clinical cancer research : CR 25 36229838
2015 Vibrio vulnificus VvpE Stimulates IL-1β Production by the Hypomethylation of the IL-1β Promoter and NF-κB Activation via Lipid Raft-Dependent ANXA2 Recruitment and Reactive Oxygen Species Signaling in Intestinal Epithelial Cells. Journal of immunology (Baltimore, Md. : 1950) 25 26223656
2024 Stabilization of MOF (KAT8) by USP10 promotes esophageal squamous cell carcinoma proliferation and metastasis through epigenetic activation of ANXA2/Wnt signaling. Oncogene 24 38317006
2021 The ANXA2/S100A10 Complex-Regulation of the Oncogenic Plasminogen Receptor. Biomolecules 24 34944416
2018 Biological Effect and Mechanism of the miR-23b-3p/ANXA2 Axis in Pancreatic Ductal Adenocarcinoma. Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology 24 30355917
2019 Anxa2- and Ctsd-knockout CHO cell lines to diminish the risk of contamination with host cell proteins. Biotechnology progress 23 30972970
2019 ANXA2 Silencing Inhibits Proliferation, Invasion, and Migration in Gastric Cancer Cells. Journal of oncology 22 31186633
2019 A combined ANXA2-NDRG1-STAT1 gene signature predicts response to chemoradiotherapy in cervical cancer. Journal of experimental & clinical cancer research : CR 22 31242951
2018 Anxa2 attenuates osteoblast growth and is associated with hip BMD and osteoporotic fracture in Chinese elderly. PloS one 22 29570731
2023 FBXW10-S6K1 promotes ANXA2 polyubiquitination and KRAS activation to drive hepatocellular carcinoma development in males. Cancer letters 21 37277019
2020 Circ-EEF2 facilitated autophagy via interaction with mir-6881-3p and ANXA2 in EOC. American journal of cancer research 21 33294264
2016 ANXA2 enhances the progression of hepatocellular carcinoma via remodeling the cell motility associated structures. Micron (Oxford, England : 1993) 21 27060670
2021 ANXA2 Facilitates Enterovirus 71 Infection by Interacting with 3D Polymerase and PI4KB to Assist the Assembly of Replication Organelles. Virologica Sinica 20 34196914
2017 A new cis-acting motif is required for the axonal SMN-dependent Anxa2 mRNA localization. RNA (New York, N.Y.) 20 28258160
2015 RNAi-mediated silencing of Anxa2 inhibits breast cancer cell proliferation by downregulating cyclin D1 in STAT3-dependent pathway. Breast cancer research and treatment 20 26253946
2000 S100 protein-annexin interactions: a model of the (Anx2-p11)(2) heterotetramer complex. Biochimica et biophysica acta 20 11108962
2025 Lactylation-driven USP4-mediated ANXA2 stabilization and activation promotes maintenance and radioresistance of glioblastoma stem cells. Cell death and differentiation 19 40185997
2024 NINJ1 Facilitates Abdominal Aortic Aneurysm Formation via Blocking TLR4-ANXA2 Interaction and Enhancing Macrophage Infiltration. Advanced science (Weinheim, Baden-Wurttemberg, Germany) 19 38922800
2015 A novel Anxa2-interacting protein Ebp1 inhibits cancer proliferation and invasion by suppressing Anxa2 protein level. Molecular and cellular endocrinology 19 25917452
2021 Interaction of FLNA and ANXA2 promotes gefitinib resistance by activating the Wnt pathway in non-small-cell lung cancer. Molecular and cellular biochemistry 18 34018148
2019 Interaction of HE4 and ANXA2 exists in various malignant cells-HE4-ANXA2-MMP2 protein complex promotes cell migration. Cancer cell international 18 31210752
2017 Identifying low density lipoprotein cholesterol associated variants in the Annexin A2 (ANXA2) gene. Atherosclerosis 18 28456096
2023 Machine learning identifies ferroptosis-related gene ANXA2 as potential diagnostic biomarkers for NAFLD. Frontiers in endocrinology 17 38192427
2024 Microplastics accumulated in breast cancer patients lead to mitophagy via ANXA2-mediated endocytosis and IL-17 signaling pathway. Environmental pollution (Barking, Essex : 1987) 16 39557355
2023 METTL3-mediated ANXA2 inhibition confers neuroprotection in ischemic stroke: Evidence from in vivo and in vitro studies. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 16 37249328
2018 ANXA2 expression in African American triple-negative breast cancer patients. Breast cancer research and treatment 16 30478786
2024 Dissecting the MUC5AC/ANXA2 signaling axis: implications for brain metastasis in lung adenocarcinoma. Experimental & molecular medicine 15 38825648
2024 ADAM8 deficiency in macrophages promotes cardiac repair after myocardial infarction via ANXA2-mTOR-autophagy pathway. Journal of advanced research 15 39097092
2022 The mouse Anxa6/miR-9-5p/Anxa2 axis modulates TGF-β1-induced mouse hepatic stellate cell (mHSC) activation and CCl4-caused liver fibrosis. Toxicology letters 15 35483553
2008 Equine ANXA2 and MMP1 expression analyses in an experimental model of normal and pathological wound repair. Journal of dermatological science 15 18434095
2024 m6A Modification of Profilin-1 in Vascular Smooth Muscle Cells Drives Phenotype Switching and Neointimal Hyperplasia via Activation of the p-ANXA2/STAT3 Pathway. Arteriosclerosis, thrombosis, and vascular biology 14 39508106
2022 Annexin A2 (ANXA2) regulates the transcription and alternative splicing of inflammatory genes in renal tubular epithelial cells. BMC genomics 14 35906541
2019 High levels of ANXA2 are characteristic of malignant salivary gland tumors. Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology 14 31325182
2014 ERG oncoprotein inhibits ANXA2 expression and function in prostate cancer. Molecular cancer research : MCR 14 25344575
2012 Effect of ANXA2 gene single nucleotide polymorphism (SNP) on the development of osteonecrosis in Indian sickle cell patient: a PCR-RFLP approach. Indian journal of experimental biology 14 22822523
2022 2D transparent few-layered hydrogen substituted graphdiyne nano-interface for unprecedented ultralow ANXA2 cancer biomarker detection. Biosensors & bioelectronics 13 35696865
2021 Long noncoding RNA LINC00184 facilitates the proliferation, metastasis, and adenine metabolism of cholangiocarcinoma via modulating hsa-miR-23b-3p/ANXA2 axis. Environmental toxicology 13 33913242
2021 The S100A10-AnxA2 complex is associated with the exocytosis of hepatitis B virus in intrauterine infection. Laboratory investigation; a journal of technical methods and pathology 13 34645932
2020 ANXA2 is a potential marker for the diagnosis of human cervical cancer. Biomarkers in medicine 13 33315468
2019 ANXA2, PRKCE, and OXT are critical differentially genes in Nonalcoholic fatty liver disease. Gastroenterology and hepatology from bed to bench 13 31191837
2023 Upregulation of HDAC9 in hippocampal neurons mediates depression-like behaviours by inhibiting ANXA2 degradation. Cellular and molecular life sciences : CMLS 12 37690046
2022 Inhibition of ANXA2 regulated by SRF attenuates the development of severe acute pancreatitis by inhibiting the NF-κB signaling pathway. Inflammation research : official journal of the European Histamine Research Society ... [et al.] 12 35900381
2024 Exosomal ANXA2 facilitates ovarian cancer peritoneal metastasis by activating peritoneal mesothelial cells through binding with TLR2. Cell communication and signaling : CCS 11 39709496
2022 Annexin A2 (AnxA2) association with the clinicopathological data in different breast cancer subtypes: A possible role for AnxA2 in tumor heterogeneity and cancer progression. Life sciences 11 36116530
2021 CircRNA ANXA2 Promotes Lung Cancer Proliferation and Metastasis by Upregulating PDPK1 Expression. Journal of oncology 11 34992655
2024 METTL3-mediated deficiency of lncRNA HAR1A drives non-small cell lung cancer growth and metastasis by promoting ANXA2 stabilization. Cell death discovery 10 38688909
2024 NUSAP1 promotes gastric cancer radioresistance by inhibiting ubiquitination of ANXA2 and is suppressed by miR-129-5p. Journal of cancer research and clinical oncology 10 39212774
2023 FGF19 promotes nasopharyngeal carcinoma progression by inducing angiogenesis via inhibiting TRIM21-mediated ANXA2 ubiquitination. Cellular oncology (Dordrecht, Netherlands) 10 37782406
2022 AMG487 inhibits PRRSV replication and ameliorates lung injury in pig lung xenografts by down-regulating the expression of ANXA2. Antiviral research 10 35405171
2021 Radiation engenders converse migration and invasion in colorectal cancer cells through opposite modulation of ANXA2/AKT/GSK3β pathway. American journal of cancer research 10 33520360
2025 Interaction with IGF1 overrides ANXA2-mediated anti-inflammatory functions of IGFBP5 in vivo. Frontiers in immunology 9 39867883

Missed literature

Know a paper Affinage missed for ANXA2? Flag it for the maintainers and the community.

No submissions yet.